Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
The company has received five final approvals
Furthering cell therapy ambition across oncology and autoimmune diseases
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
Subscribe To Our Newsletter & Stay Updated
